Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01482052
Recruitment Status : Completed
First Posted : November 30, 2011
Last Update Posted : January 14, 2013
Information provided by (Responsible Party):
JN-International Medical Corporation

Brief Summary:
The purpose of this study is to evaluate the safety of a new conjugate vaccine, NmVac4-A/C/Y/W-135-DT, compared to the safety of a similar, licensed meningococcal A/C/Y/W-135-DT conjugate vaccine. The investigators will also evaluate the production of antibodies to of NmVac4-A/C/Y/W-135-DT™ conjugate vaccine compared to the licensed vaccine, as a measure of vaccine effectiveness.

Condition or disease Intervention/treatment Phase
Meningococcal Meningitis Meningococcal Infections Biological: meningococcal meningitis conjugate vaccine, quadrivalent Phase 1

Detailed Description:
Meningococcal disease is a potentially life-threatening bacterial infection. The disease most commonly is expressed as either meningococcal meningitis, an inflammation of the membranes surrounding the brain and spinal cord, or meningococcemia, the presence of bacteria in the blood. The most common symptoms include high fever, headache, neck stiffness, confusion, nausea, vomiting, lethargy, and rash. If not treated the disease can progress rapidly and can lead to shock and death, often within hours of the onset of symptoms. Neisseria meningitidis capsular polysaccharides are poor immunogens. However, conjugation of bacterial polysaccharides to immunogenic carrier proteins generally results in conjugates that induce strong anti-polysaccharide T-helper cell dependent immune responses, creating a longer-lasting immune response and thus protection against meningococcal infection. This study compares safety and antibody production induced by one intramuscular injection of either NmVac4-A/C/Y/W-135-DT or a licensed meningococcal A/C/Y/W-135-DT conjugate vaccine. Participants will attend a screening visit up to 4 weeks prior to Day 0, then will attend study visits for 8 weeks. There will be a study phone call at Days 2-3, then a post-study telephone call to subjects to assess safety at 26 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Double-Blind, Randomized, Controlled, Two Arm Phase 1 Clinical Trial of the Safety and Immunogenicity of Group A, C, Y & W-135 Meningococcal Polysaccharide DT Conjugate Vaccine: NmVac4-A/C/Y/W-135-DT™
Study Start Date : November 2011
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013

Arm Intervention/treatment
Experimental: Test Vaccine
NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
Biological: meningococcal meningitis conjugate vaccine, quadrivalent
NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
Other Name: NmVac4-A/C/Y/W-135-DT™

Active Comparator: US Licensed Vaccine
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological: meningococcal meningitis conjugate vaccine, quadrivalent
Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.

Primary Outcome Measures :
  1. Adverse Reactions [ Time Frame: up to 6 months ]
    local and systemic rates throughout the course of the study

Secondary Outcome Measures :
  1. Immune Response [ Time Frame: 4 and 8 weeks after injection ]
    Antibody titers

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Willing and able to give informed consent and comply with all aspects of the evaluation after the nature of the study is explain
  • For the purpose of this study, a healthy volunteer is defined as healthy male or female, with no significant chronic conditions
  • Age 18 to 50 years old
  • Either gender. Abstinence or use of contraception during the eight weeks after vaccination will be required for non menopausal (< two years post-menopause) or non surgically sterile women
  • Persons with antibody titer(s) of <2 µg/mL to serogroup(s) A, C, Y, or W-135 polysaccharides as measured by ELISA

Exclusion Criteria:

  • Age less than 18 years or over 50 years.
  • History of Guillain-Barré syndrome (GBS).
  • Pregnancy or lactation.
  • History of meningococcal meningitis.
  • History of invasive (clinical or laboratory diagnosis) meningococcal disease.
  • History of meningococcal meningitis vaccination.
  • Screening laboratory abnormalities (in the opinion of the Investigator) that would raise safety concerns for participation in the study.
  • Use of immunosuppressive drugs within 30 days prior to study enrollment, not including topical or inhaled steroids/cytotoxic agents.
  • History of anaphylactic shock, asthma, urticaria, or other allergic or hypersensitivity reactions following vaccination.
  • History of severe allergic disorders or autoimmune connective tissue disorders, including rheumatoid arthritis. A high sensitivity C-Reactive Protein (CRP) test at screening will be used as part of the assessment of autoimmune disorders by the Principal Investigator.
  • Use of systemic antibiotics within 72 hours prior to study enrollment.
  • History of cirrhosis.
  • Positive results of testing for HepBsAg, Hepatitis C or HIV-1 or HIV-2 antibodies.
  • Positive results of drug screen (amphetamine, THC, cocaine).
  • Persons with antibody titer(s) of >2 µg/mL to serogroup (s) A, C, Y, or W 135 as measured by ELISA.
  • Unable to understand all of the study requirements.
  • Prisoners.
  • Participation in a clinical trial in the last three months.
  • History of any serious chronic medical or psychiatric illnesses.
  • History of significant head trauma, alcohol or substance abuse or other medical illnesses that could cause a neurological deficit (e.g., cerebro-vascular disease) .
  • Chronic medication use that, in the opinion of the Investigator, may influence or bias the clinical outcome of the trial.
  • Individuals will be excluded from participation in this trial if they are judged by the Principal Investigator as having a significant impairment in their capacity for judgment or reasoning that compromise their ability to make decisions in their best interest.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01482052

Layout table for location information
United States, California
Kings Cardiology Group
Hanford, California, United States, 93230
Sponsors and Collaborators
JN-International Medical Corporation
Layout table for investigator information
Principal Investigator: Sudesh Nagavalli, MD
Layout table for additonal information
Responsible Party: JN-International Medical Corporation Identifier: NCT01482052    
Other Study ID Numbers: JN-NM-001
First Posted: November 30, 2011    Key Record Dates
Last Update Posted: January 14, 2013
Last Verified: January 2013
Keywords provided by JN-International Medical Corporation:
Central Nervous System Infections
Meningococcal vaccine
conjugate vaccines
Additional relevant MeSH terms:
Layout table for MeSH terms
Meningococcal Infections
Meningitis, Meningococcal
Central Nervous System Diseases
Nervous System Diseases
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Meningitis, Bacterial
Central Nervous System Bacterial Infections
Central Nervous System Infections
Immunologic Factors
Physiological Effects of Drugs